(ASPI) ASP Isotopes Common Stock - NASDAQ

Sector: Basic Materials | Industry: Chemicals | Exchange: NASDAQ (USA) | Market Cap: 825m USD | Total Return: -17.1% in 12m

Nuclear Fuels, Medical Isotopes, Semiconductor Materials
Total Rating 20
Safety 30
Buy Signal -1.58
Chemicals
Industry Rotation: -12.9
Market Cap: 825M
Avg Turnover: 37.5M
Risk 3d forecast
Volatility120%
VaR 5th Pctl19.3%
VaR vs Median-2.09%
Reward TTM
Sharpe Ratio0.26
Rel. Str. IBD34.4
Rel. Str. Peer Group27.6
Character TTM
Beta2.235
Beta Downside1.962
Hurst Exponent0.430
Drawdowns 3y
Max DD71.03%
CAGR/Max DD2.19
CAGR/Mean DD4.83

Warnings

Share dilution 74.1% YoY

Interest Coverage Ratio -33.4 is critical

Beneish M-Score 1.00 > -1.5 - likely earnings manipulation

Altman Z'' 0.92 < 1.0 - financial distress zone

Choppy Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: ASPI ASP Isotopes Common Stock

ASP Isotopes Inc. (ASPI) is a development-stage materials company focused on the production and distribution of isotopes via two primary segments: Nuclear Fuels and Specialist Isotopes. The company utilizes proprietary Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE) technologies to isolate specific isotopes for high-growth sectors, including advanced nuclear energy, medical imaging, and semiconductor manufacturing.

The company’s Nuclear Fuels division specifically targets the production of High-Assay Low-Enriched Uranium (HALEU) and Lithium-6, which are critical components for the next generation of small modular reactors. Isotope enrichment is a highly specialized niche within the materials sector, characterized by significant technical barriers to entry and a reliance on complex gas-phase separation methods.

For a deeper look into the companys financial health and valuation metrics, consider reviewing the latest data on ValueRay. Based in Dallas, Texas, ASP Isotopes also commercializes isotopes like Molybdenum-100 and Ytterbium-176 for the pharmaceutical industry while developing additional materials for the agrochemical and electronics markets.

Headlines to Watch Out For
  • HALEU production milestones drive valuation as advanced nuclear reactor demand increases
  • Aerodynamic Separation Process technology commercialization determines long-term margin potential
  • Supply contracts for medical isotopes like Molybdenum-100 impact near-term revenue growth
  • Strategic partnerships in semiconductor and pharmaceutical sectors diversify isotope application risk
  • Capital expenditure requirements for enrichment facilities influence liquidity and share dilution risks
Piotroski VR-10 (Strict) 0.5
Net Income: -173.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.28 > 0.02 and ΔFCF/TA 13.00 > 1.0
NWC/Revenue: 885.2% < 20% (prev 1.15k%; Δ -268.8% < -1%)
CFO/TA -0.09 > 3% & CFO -52.4m > Net Income -173.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.39 > 1.5 & < 3
Outstanding Shares: last quarter (121.0m) vs 12m ago 74.14% < -2%
Gross Margin: 17.62% > 18% (prev 37.40%; Δ -19.78% > 0.5%)
Asset Turnover: 7.94% > 50% (prev 4.85%; Δ 3.09% > 0%)
Interest Coverage Ratio: -33.44 > 6 (EBIT TTM -74.1m / Interest Expense TTM 2.22m)
Altman Z'' 0.92
A: 0.41 (Total Current Assets 308.7m - Total Current Liabilities 70.4m) / Total Assets 587.7m
B: -0.41 (Retained Earnings -238.5m / Total Assets 587.7m)
C: -0.22 (EBIT TTM -74.1m / Avg Total Assets 339.3m)
D: 1.00 (Book Value of Equity 289.0m / Total Liabilities 288.7m)
Altman-Z'' = 0.92 = BB
Beneish M 1.00
DSRI: 1.08 (Receivables 4.59m/692k, Revenue 26.9m/4.41m)
GMI: 2.12 (GM 37.40% / 17.62%)
AQI: 5.24 (AQ_t 0.31 / AQ_t-1 0.06)
SGI: 6.11 (Revenue 26.9m / 4.41m)
TATA: -0.21 (NI -173.5m - CFO -52.4m) / TA 587.7m)
Beneish M = 4.22 (Cap -4..+1) = D
What is the price of ASPI shares?

As of June 15, 2026, the stock is trading at USD 6.55 with a total of 5,149,864 shares traded.
Over the past week, the price has changed by -2.38%, over one month by +7.55%, over three months by +22.66% and over the past year by -17.09%.

Is ASPI a buy, sell or hold?

ASP Isotopes Common Stock has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy ASPI.

  • StrongBuy: 1
  • Buy: 0
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ASPI price?
Analysts Target Price 13 98.5%
ASP Isotopes Common Stock (ASPI) - Fundamental Data Overview as of 13 June 2026
Market Cap USD = 824.7m (824.7m USD * 1.0 USD.USD)
P/E Forward = 54.3478
P/S = 30.626
P/B = 2.7141
Revenue TTM = 26.9m USD
EBIT TTM = -74.1m USD
EBITDA TTM = -69.3m USD
Long Term Debt = 205.0m USD (from longTermDebt, last quarter)
Short Term Debt = 54.2m USD (from shortTermDebt, last quarter)
Debt = 265.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 3.62m
Net Debt = -25.1m USD (calculated: Debt 265.5m - CCE 290.5m)
Enterprise Value = 799.6m USD (824.7m + Debt 265.5m - CCE 290.5m)
Interest Coverage Ratio = -33.44 (Ebit TTM -74.1m / Interest Expense TTM 2.22m)
EV/FCF = -4.88x (Enterprise Value 799.6m / FCF TTM -163.9m)
FCF Yield = -20.50% (FCF TTM -163.9m / Enterprise Value 799.6m)
 FCF Margin = -608.8% (FCF TTM -163.9m / Revenue TTM 26.9m)
 Net Margin = -644.4% (Net Income TTM -173.5m / Revenue TTM 26.9m)
 Gross Margin = 17.62% ((Revenue TTM 26.9m - Cost of Revenue TTM 22.2m) / Revenue TTM)
Gross Margin QoQ = 39.86% (prev 12.50%)
Tobins Q-Ratio = 1.36 (Enterprise Value 799.6m / Total Assets 587.7m)
Interest Expense / Debt = 0.84% (Interest Expense 2.22m / Debt 265.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -58.6m (EBIT -74.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.00 (Total Current Assets 308.7m / Total Current Liabilities 77.2m)
Debt / Equity = 0.92 (Debt 265.5m / totalStockholderEquity, last quarter 289.0m)
 Debt / EBITDA = 0.36 (negative EBITDA) (Net Debt -25.1m / EBITDA -69.3m)
 Debt / FCF = 0.15 (negative FCF - burning cash) (Net Debt -25.1m / FCF TTM -163.9m)
 Total Stockholder Equity = 148.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -51.15% (Net Income -173.5m / Total Assets 587.7m)
RoE = -117.2% (Net Income TTM -173.5m / Total Stockholder Equity 148.1m)
RoCE = -21.00% (EBIT -74.1m / Capital Employed (Equity 148.1m + L.T.Debt 205.0m))
 RoIC = -10.27% (negative operating profit) (NOPAT -58.6m / Invested Capital 570.2m)
 WACC = 10.63% (E(824.7m)/V(1.09b) * Re(13.84%) + D(265.5m)/V(1.09b) * Rd(0.84%) * (1-Tc(0.21)))
Discount Rate = 13.84% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 91.11 | Cagr: 49.55%
 [DCF] Fair Price = unknown (Cash Flow -163.9m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.61 | # QB: 0
Revenue Correlation: 99.73 | Revenue CAGR: 642.1% | SUE: 0.08 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.31 | Chg30d=-12.22% | Revisions=-20% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.29 | Chg30d=-11.39% | Revisions=-20% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.47 | Chg30d=+55.80% | Revisions=-20% | GrowthEPS=+43.4% | GrowthRev=+27.8%
EPS next Year (2027-12-31): EPS=-1.16 | Chg30d=-10.51% | Revisions=-20% | GrowthEPS=-146.1% | GrowthRev=+187.6%
[Analyst] Revisions Ratio: -20%